Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S
Department of Urology, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650, Japan.
Int J Oncol. 1998 Feb;12(2):469-73. doi: 10.3892/ijo.12.2.469.
The mutant p53 gene was transfected into ACHN, a wild-type p53-containing human renal cell carcinoma (RCC) cell line. The colony forming efficiency in soft agar in the mutant-type p53-transfected cell line (ACHN/MP) was significantly higher than that in the vector-only transfected control cell line (ACHN/C). The anti-Fas monoclonal antibody (CH11) induced apoptosis in the ACHN/C cells in a dose-dependent manner, whereas the effect of CH11 on the ACHN/ MP cells was markedly suppressed. In addition, the cytotoxic effect of CH11 on the ACHN/MP cells was augmented by the pretreatment with interferon- , but the corresponding effect on ACHN/C cells was not. These findings suggest that Fas-mediated therapy could be a novel approach to RCC, if interferon- treatment is added according to the p53 gene status.
将突变型p53基因转染至ACHN细胞,这是一种含野生型p53的人肾细胞癌(RCC)细胞系。在转染突变型p53的细胞系(ACHN/MP)中,软琼脂中的集落形成效率显著高于仅转染载体的对照细胞系(ACHN/C)。抗Fas单克隆抗体(CH11)以剂量依赖方式诱导ACHN/C细胞凋亡,而CH11对ACHN/MP细胞的作用则受到明显抑制。此外,用干扰素-预处理可增强CH11对ACHN/MP细胞的细胞毒性作用,但对ACHN/C细胞则无相应作用。这些发现表明,如果根据p53基因状态添加干扰素-治疗,Fas介导的疗法可能是一种治疗RCC的新方法。